The programme is designed to support early-stage biotech companies in getting their biologic or cell & gene therapy products and technologies to market
Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.